COMPASS Pathways plc
COMPASS Pathways is a clinical-stage psychedelic-medicine biotech with minimal political/regulatory footprint, focused on psilocybin-assisted therapy for treatment-resistant depression.
BusinessWhat CMPS does
COMPASS Pathways develops proprietary psilocybin formulations and delivery protocols for psychiatric indications, primarily treatment-resistant depression. Revenue is pre-commercial; the company is funded via equity raises and operates under FDA Breakthrough Therapy designation. Primary exposure is to FDA drug-approval timelines and psychedelic rescheduling policy.
12 months past · 3 months futureCMPS activity timeline
Lifetime Government AwardsCMPS federal contracts
CMPS doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding CMPS
Congressional TradesWho in Congress is trading CMPS
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere CMPS sits in Washington
Pre-revenue biotech with no active lobbying, campaign donations, or politician trading. Stock moves on clinical trial results and FDA decisions, not legislative/regulatory news cycles.
Regulatory ExposureThreats & opportunities
Regulatory threats
- DEA rescheduling delays
- FDA clinical-trial design requirements
- manufacturing/GMP compliance
Regulatory opportunities
- FDA Breakthrough Therapy pathway acceleration
- psychedelic rescheduling to Schedule III
- expanded clinical-trial access
Live signals + predictions for CMPS — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades CMPS
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord